Discovery of a Novel A<sub>2B</sub> Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases
作者:Elfatih Elzein、Rao V. Kalla、Xiaofen Li、Thao Perry、Art Gimbel、Dewan Zeng、David Lustig、Kwan Leung、Jeff Zablocki
DOI:10.1021/jm7014815
日期:2008.4.1
discovery of compound 62, that displayed high affinity and selectivity for the hA(2B)-AdoR (K(i) = 22 nM). In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcarboxamidoadenosine in HEK-A(2B)-AdoR and NIH3T3 cells with K(B) values of 6 and 2 nM, respectively. In a single ascending-dose phase I clinical study, compound
最近,我们已经报道了一系列新的1,3对称(R 1 = R 3)取代的黄嘌呤(3和4),它们对人腺苷A 2B受体(hA(2B)-AdoR)具有高亲和力和选择性。不幸的是,这类化合物的药代动力学性能较差。这促使我们研究在N-1和N-3位置(N 1-R不等于N 3-R)的差异烷基取代对A(2B)-AdoR亲和力和选择性的影响。我们的双重目标是增强对A(2B)-AdoR的亲和力和选择性,以及提高口服生物利用度。这项工作导致发现了化合物62,该化合物显示出对hA(2B)-AdoR(K(i)= 22 nM)的高亲和力和选择性。另外,化合物62在抑制5'诱导的环状磷酸腺苷蓄积中显示出高功能性。-HEK-A(2B)-AdoR和NIH3T3细胞中的N-乙基羧酰胺基腺苷,其K(B)值分别为6和2 nM。在一项单剂量的I期临床研究中,化合物62没有严重的不良事件,并且具有良好的耐受性。